Kornimate/medical-research-clean huggingface dataset:
pipaf platelets in the pathogenesis of ageing associated frailty

Conditions: Coronary Artery Disease; Diabetes Mellitus, Type 2; Alzheimer Disease

Summary: this is a prospective observational study aimed at testing the existence of an association between frailty, inflammatory status, and degree of platelet activation and reactivity in elderly subjects with type 2 diabetes or coronary artery disease or alzheimer's disease.

frailty in the elderly is a syndrome that strongly affects quality of life and represents a major social and economic challenge. frailty often, and more frequently, occurs in individuals with aging-related diseases including type 2 diabetes, cardiovascular disease, and alzheimer's disease. all of these diseases are associated with a state of weak chronic inflammation. studies in recent years have pointed out that platelets can directly contribute to inflammatory processes. due to of this ability to act as proinflammatory cells and of their strong involvement in various metabolic, cardiovascular, and neurodegenerative disorders, platelets appear to have key roles in the physio-pathological mechanisms that predispose to frailty. in the present study, it is planned to recruit 4 cohorts of elderly patients, each of 40 patients, divided by pathology ( frail elderly, diabetic elderly, elderly with stable atherosclerotic coronary artery disease, elderly with early-stage alzheimer's disease) and a cohort of 40 healthy elderly subjects. all subjects will perform a blood draw at enrollment and after 24 months of follow up in order to evaluate: the state of platelet activation; the aggregating response of platelets to stimuli such as thrombin, adenosine diphosphate (adp), and collagen; the state of chronic inflammation and oxidative stress; the procoagulant profile of platelets; presence of platelet subpopulations characterized by rna, microrna and/or protein profiling. each subject will also be given a questionnaire to assess frailty status (according to fried's criteria) and urine samples will be collected to perform the assay of metabolites such as 11dh-txb, 8-hydroxy-2-deoxyguanosine (8-ohdg) and 8-epipgf2a (8-isoprostane).

Eligibility criteria:
inclusion criteria: * age \> 65 years * low-dose aspirin therapy (100 mg) * belonging to each of the cohorts indicated exclusion criteria: * lack of inclusion criteria and/or consent to the study

Keywords: coronary artery disease diabetes mellitus, type 2 alzheimer disease platelets
evaluation of efficacy and safety of brazikumab (medi2070) in participants with active, moderate to severe crohn's disease

Conditions: Crohn's Disease

Summary: a phase 2b study to evaluate the efficacy and safety of brazikumab (medi2070) in participants with moderate to severe crohn's disease who have failed or are intolerant to anti-tumor necrosis factor-alpha (anti-tnfα) therapy.

this is a four-part phase 2b study comprised of a 16-week, double-blind, placebo-controlled, induction period, a 12-week double-blind, placebo-controlled, maintenance period, a 24-week, open-label period and a post-treatment 28 week observational safety follow-up period designed to evaluate the short-term efficacy and the short- and long term safety of brazikumab in participants with moderate to severe, active crohn's disease (cd) who have failed or are intolerant to anti-tnfα therapy as determined by the investigator.

Eligibility criteria:
inclusion criteria: * diagnosis of ileal, ileo-colonic, or colonic crohn's disease (cd) for \> 3 months prior to screening * men or women age 18 - 80 years at the time of screening * moderate to severely active cd, as defined by crohn's disease activity index (cdai) and endoscopic demonstration of inflammation * stable dose of medications for crohn's disease therapy * prior treatment failure or intolerance with at least one anti-tumor necrosis factor-alpha therapy (anti-tnf α) agent * effective contraception from screening, and for 36 weeks after the last dose of investigational product * no known history of active tuberculosis (tb) \& negative assessment for tb/latent tb exclusion criteria: * severe underlying immunosuppression * severe gastrointestinal complications; e.g., short bowel syndromes, obstructing strictures, recent or planned bowel surgery, ileostomy and/or colostomy, recent bowel perforation * significant infections at screening; infected abscess, positive for clostridium difficile, recent infectious hospitalization * recent treatment with approved or investigational biologic therapy for crohn's disease * recent or planned live attenuated vaccine * history of cancer, except for basal cell carcinoma or carcinoma in situ (cis) of the cervix with apparent cure ≥ 12 months before screening * pregnancy/breast feeding * drug abuse

Keywords: medi2070 inflammatory bowel disease moderate to severe crohn's disease il-23
scouting nutrition and activity program

Conditions: Obesity

Summary: the purpose of the study was to evaluate the effectiveness of an intervention designed to prevent obesity by improving the environmental characteristics of girl scouts troop meetings.

girls and parents affiliated with girl scouts juniors programs completed a questionnaire prior to the beginning of an intervention program, and again after the program. children responded to previously validated questionnaire items assessing demographics, parent-child connectedness, parent-child physical activity, screen time usage, family meal-time environment, consumption of fruits and vegetables, soda, and fast food. parents completed a similar questionnaire, assessing demographics, parent-child connectedness, parent-child physical activity, family mealtime environment, parenting style and parenting practices. children were also assessed on height and weight to characterize their risk for overweight status. questionnaires and environmental observations were used to assess the effectiveness of an intervention designed to improve the family meal-time environment at home, as well as helping to assess the relationships between parental factors and family health-related behavior.

Eligibility criteria:
inclusion criteria: * girls had to be attending members of girl scouts in one of our included troops. * the troop needed to be a registered girl scouts juniors troop, consisting of girls primarily in the 4th and 5th grades. * to be officially registered, the troop leaders were required to complete girl scout leader training and pass a criminal background check. * to be included, the troops also needed to meet at least twice per month, have meeting facilities capable of allowing physical activity and food preparation. * also, troops needed to have initial agreement of leaders and parents for the troop to participate in a research study. exclusion criteria: * an inability to speak or read english. * troops not primarily composed of girl scouts juniors, not regularly meeting during the study period, or not having leader and parental consensus approval for troop participation.

Keywords: obesity prevention girl scouts physical activity family meals fruits and vegetables health promotion
effect of interventions on the progression of knee osteoarthritis

Conditions: Osteo Arthritis of the Knees

Summary: there has been intensive search for a substance that can have disease-modifying activity for osteoarthritis. a number of medications have been reported to be of benefit on slowing progression of knee oa. this trial will be the first head to head comparison of these medications. patients aged between age 40 to 65 will be enrolled. patients will be assessed clinically using two scoring systems, the womac index for knee arthritis and the sf 36 for overall physical and mental health. the knee x rays will be assessed on kellgren and lawrence grading and will also be measured for joint space narrowing at follow up. the response to arthritis medications on slowing down cartilage loss will be measured biochemically with comp levels.


Eligibility criteria:
inclusion criteria: * patients of either sex aged between 40 to 65 years with mild to moderate osteoarthritis of the knees. * patients should have history of knee pain for at least 6 months and on the majority of days during the preceding month * each joint will be scored separately so one patient with bilateral knee osteoarthritis will be counted as 2 knees. * the osteoarthritis will be graded on basis of clinical score as well as seen on appropriately positioned x rays using the kellgren and lawrence grading. (tibio femoral osteophytes of at least 1 mm, kellgren lawrence grading of 2 or 3) * patients with diabetes are sent to the diabetes clinic and are included once their hba1c level becomes normal. * patients giving informed consent exclusion criteria: * patients with severe end stage tricompartmental osteoarthritis of the knees . * presence of uncontrolled systemic disease like chronic liver and renal disease * patients with diagnosis other than osteoarthritis, such as knee arthritis due to rheumatoid disease, gout, post traumatic arthritis * patients with history of surgery to any knee will have that knee excluded * pregnant or lactating mothers * patients with chronic anaemia * patients who get an injection in their affected knee
comparison of cardiac computed tomography for the detection of coronary artery disease with nuclear stress test

Conditions: Coronary Arteriosclerosis

Summary: to compare the efficacy of 16-row multi-detector ct (mdct) with standard myocardial perfusion imaging in detecting coronary artery disease (cad) in patients without a previously established diagnosis of cad.

nuclear stress testing is currently the established non-invasive modality in detecting flow-obstructing coronary artery disease (cad). recently, multi-detector ct (mdct) has emerged as a new modality that offers a non-invasive means to directly visualize coronary anatomy and any cad. studies have shown that mdct has excellent sensitivity and a high negative predictive value in detecting significant cad. the purpose of this study is to compare mdct with nuclear stress testing for detecting cad in previously undiagnosed patients.

Eligibility criteria:
inclusion criteria: * referred for a clinical indicated stress spect mpi * adequate iv access in both arms exclusion criteria: * history of coronary angioplasty or stent placement * history of coronary bypass surgery * angiographic history of flow-limiting cad * documented history of elevated cardiac markers * documented history of injury or infarct on ecg * absence of sinus rhythm * current history of renal insufficiency * known allergy to contrast dye * pregnant

Keywords: coronary arteriosclerosis tomography, x-ray computed tomography, emission-computed, single-photon
delayed effects of treatment in cancer survivors (detecs)

Conditions: Breast Cancer; Leukemia; Lymphoma; Gynecologic Cancer

Summary: hypotheses and specific aims: there is limited data on the long-term consequences of cancer therapy on young, reproductively aged cancer survivors. the investigators objective is to characterize some of these effects in the cancer population.

specific aim 1: to compare markers of ovarian reserve between cancer survivors and healthy controls. hypothesis: cancer survivors will have lower serum anti-mullerian hormone (amh) and antral follicle count (afc), and higher follicle stimulating hormone (fsh) than healthy controls. specific aim 2: to compare cardio-metabolic, endocrine and bone profiles between cancer survivors and controls using a combination of anthropometric measures, fasting serum markers, and urinary markers of bone health. hypothesis: cancer survivors will have higher total cholesterol and lower 25-oh vitamin d than healthy controls. specific aim 3: to evaluate potential associations between ovarian reserve and markers of metabolism, obesity, and tumor bone health in young female cancer survivors. hypothesis: as bmi and total cholesterol increases, serum amh will decrease. specific aim 4: to compare quality of life markers, as assessed by validated instruments, between cancer survivors and controls using recommended scoring techniques. hypothesis: cancer survivors will have lower quality of life markers as compared to controls. the investigators will conduct a prospective study to characterize the quality of life and cardio-metabolic, endocrine, and bone profiles of female cancer survivors using a combination of anthropometric, serum, urinary, and ultrasonographic markers in combination with qol instruments.

Eligibility criteria:
inclusion criteria: * exposed: females between the ages of 18 and 45, at least 2 years from the completion of cancer therapy. subjects will have one of the following cancer diagnoses: breast, leukemia, lymphoma, and/or any gynecologic cancer. subjects must also be postmenarchal, have a uterus, at least one intact ovary, and must be willing and able to comply with study procedures. subjects can be of any menopausal status and within 10 years post treatment. * unexposed: females between the ages of 18 and 45 with no prior history of cancer treatment. exclusion criteria: * exposed: pregnancy, lactation within the previous 3 months, any medical condition other than cancer with a known correlation with premature menopause (i.e. turner's syndrome, fragile x, gonadal dysgenesis, polyglandular autoimmune syndrome, lupus, etc.), hormonal contraceptive use within 3 months. * unexposed: healthy controls with a history of polycystic ovary syndrome (pcos), diabetes, thyroid dysfunction, hypertension, and hypercholesterolemia will be excluded in addition to cancer patients or survivors with one of the aforementioned diseases diagnosed prior to cancer diagnosis or treatment.

Keywords: cancer therapy, cancer treatment
high dose of amoxicillin and metronidazole plus bismuth for helicobacter pylori treatment

Conditions: Helicobacter Pylori Infection

Summary: amoxicillin and metronidazole （400mg q.d.s） based quadruple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. this study aims to evaluate the efficacy and safety of the amoxicillin and metronidazole (400mg thrice a day) based triple therapy and the addition of bismuth in the naive patients with helicobacter pylori infection.


Eligibility criteria:
inclusion criteria: * participants with non-ulcer functional dyspepsia or peptic ulcer disease * ability and willingness to participate in the study and to sign and give informed consent * confirmed h. pylori infection and with no previous treatment experience exclusion criteria: * less than 18 years old * with previous gastric surgery * major systemic diseases * pregnancy or lactation * allergy to any of the study drugs administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

Keywords: helicobacter pylori therapy
ebus-tbna vs flex 19g ebus-tbna

Conditions: Lymphadenopathy; Lung Cancer; Sarcoidosis; Lymphoma

Summary: endobronchial ultrasound (ebus) guided transbronchial needle aspiration (ebus-tbna) is an excellent tool for sampling enlarged mediastinal and hilar lymph nodes, but only provides needle aspirate samples which are often adequate for cytological examination only. more advanced histopathological and immunocytopathological assessment of tissue samples, which is particularly important in the diagnosis and staging of cancer, is often not possible with the small cellular samples obtained by ebus-tbna. a new transbronchial nodal aspiration needle (the flex 19g ebus-tbna needle) has been developed with a larger needle diameter and more flexibility at the distal end, allowing better access to some lymph nodes stations. this needle can be passed down an ebus scope and can hypothetically circumvent the deficiencies of ebus-tbna highlighted above by providing tissue adequate for histological assessment rather than cytological assessment alone. this study aims to establish whether the use of the flex 19g ebus-tbna needle can improve the diagnostic yield of ebus sampling procedures compared to the use of the conventional tbna needle, thereby allowing more accurate diagnoses and reducing the need repeat procedures or more invasive surgical biopsies, without causing an increase in complication rates. patients with enlarged mediastinal and hilar lymph nodes referred for ebus-tbna will be randomised to have their nodes sampled by either the ebus-tbna needle (conventional procedure) or the novel flex 19g ebus-tbna needle. the investigators hope to recruit 250 patients over a 24 month period.


Eligibility criteria:
inclusion criteria: * scheduled for ebus-tbna as part of clinical care * lymph nodes larger than 10mm in diameter * age \> 18 years * written informed consent exclusion criteria: * contraindication to needle biopsy (e.g. coagulopathy, anticoagulation, thrombocytopenia) * inability to obtain informed consent

Keywords: endobronchial ultrasound ebus tbna mediastinal ymphadenopathy hilar lymphadenopathy lung cancer
aspirin responsiveness in women at risk for cardiac events

Conditions: Heart Disease

Summary: the objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for chd taking low dose (81 mg) aspirin. aspirin responsiveness will be measured with the verifynow device (accumetrics; san diego, ca). those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.


Eligibility criteria:
inclusion criteria: * women at least 19 years old * taking 81 mg aspirin daily, non-enteric coated, for at least one month for the primary prevention of cardiovascular disease. * able and willing to provide informed consent exclusion criteria: * pregnancy or breastfeeding * known chd * currently taking clopidogrel or ticlopidine * use of heparin, warfarin, or glycoprotein iib/iiia inhibitors within previous 96 hours * allergy or hypersensitivity to salicylates * use of other otc or prescription analgesics or anti-inflammatory medication in the past two weeks * currently participating in another investigational drug or device study
inflammatory bowel disease and atherosclerosis development

Conditions: Inflammatory Bowel Diseases; Cardiovascular Diseases; Inflammation; Arterial Stiffness

Summary: the study will show the influence of inflammatory bowel disease on the risk of development of atherosclerosis


Eligibility criteria:
inclusion criteria: * inflammatory bowel disease * signed informed consent exclusion criteria: * pregnancy * other conditions affecting the prognosis * psychiatric disorders affecting the participation in the study
study to evaluate the safety, tolerability, and efficacy of amg 827 in subjects with psoriasis

Conditions: Psoriasis

Summary: the study evaluated the efficacy of amg 827 compared with placebo as measured by the percent of improvement in pasi score at week 12.

the study evaluated the efficacy of amg 827 compared with placebo as measured by the percent of improvement in pasi score at week 12. subjects were randomized ina 1:1:1:1:1 ratio. subjects randomized to receive amg 827 received 70, 140, or 210 mg at day 1 and weeks 4 and 8.

Eligibility criteria:
inclusion criteria: * subject has had stable moderate to severe plaque psoriasis for at least 6 months * subject has received at least one previous phototherapy or systemic psoriasis therapy or has been a candidate to receive phototherapy or systemic psoriasis therapy in the opinion of the investigator. * subject has involved bsa ≥ 10% and pasi ≥ 12 at screening and at baseline. exclusion criteria: * subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced, or medication-exacerbated psoriasis. * evidence of skin conditions at the time of the screening visit (eg, eczema, guttate psoriasis) that would interfere with evaluations of the effect of ip on psoriasis. * subject has any active ctcae grade 2 or higher infection * subject has a significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol. * subject has used the following therapies within 14 days of the first dose: uvb therapy or topical psoriasis therapies other than class i or ii topical steroids * subject has used the following therapies within 28 days of the first dose: class i or ii topical steroids, uva therapy (with or without psoralen), or systemic psoriasis therapies * subject has used the following therapies within 3 months of the first dose: adalimumab, alefacept, etanercept, infliximab, certolizumab, or live vaccines * subject has used an anti-il12/il23 inhibitor within 6 months of the first dose * subject has previously used an anti-il17 biologic therapy, efalizumab, or rituximab
salivary expression of sox7 in oral squamous cell carcinoma: diagnostic accuracy study

Conditions: Oral Cancer; Oral Squamous Cell Carcinoma

Summary: the study will include patients with oral cancer and healthy controls of both sexes. subjects having any systemic diseases or other types of cancer will be excluded. all subjects will be selected from oral medicine department, faculty of dentistry, al ahram canadian university and fayoum university. informed consent will be obtained from all subjects enrolled in this study after explanation of the whole procedure.


Eligibility criteria:
inclusion criteria: * patients with oral cancer exclusion criteria: * any systemic diseases or other types of cancer will be excluded
incidence and prognostic significance of her-2 status discordance between primary breast cancer and paired recurrent/metastatic lesions

Conditions: Breast Cancer

Summary: about a half of her2-negative breast cancer show her2-low expression that can be targeted by new antibody-drug conjugates. the main aim of this study is to describe the evolution of her2 expression from primary bc to relapse by including her2-low category in both primary and recurrent bc samples. patients with matched primary and relapse bc samples were included. 1299 patients were included.


Eligibility criteria:
inclusion criteria: patients with available her2 status of primary breast cancer and relapse/metastases exclusion criteria: patients with other malignancy